Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 5/2020

01-08-2020 | Schizophrenia | Original Paper

A follow-up study of metabolic syndrome in schizophrenia

Authors: Gökhan Yoca, A. Elif Anıl Yağcıoğlu, Nurhayat Eni, Sevilay Karahan, İnci Türkoğlu, Emine Akal Yıldız, Seyit M. Mercanlıgil, M. Kâzım Yazıcı

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 5/2020

Login to get access

Abstract

The prevalence of metabolic syndrome (MetS) in schizophrenia patients is increasing worldwide. The aim of the current study was to examine the progress of MetS in a schizophrenia cohort we had previously investigated and determine the role of various related factors, including sociodemographic and clinical variables, nutritional status and physical activity. Of the 319 patients investigated in the first study, 149 patients agreed to be included in the follow-up. Physical measurements and laboratory tests were performed in addition to evaluations with the Positive and Negative Syndrome Scale, Udvalg for Kliniske Undersogelser Side Effects Scale, International Physical Activity Questionnaire, 24 h dietary recall method and Nutrition Information Systems Package Program. According to the ATPIII, ATPIIIA and IDF criteria, the MetS prevalences had increased from 35.6 to 44.3%, 38.9 to 53% and 43.6 to 55.7%, respectively. Patients with MetS had a shorter period of hospitalization and a higher UKU total side effects score, and most of them were married or divorced/widowed. Patients with MetS also had a higher daily consumption of added sugar, cholesterol, polyunsaturated fatty acids and omega 3 fatty acid, and the daily added sugar intake was found to be related to the increase in MetS. Unexpectedly, the physical activity level was not found to significantly differ in the patients with and without MetS. In conclusion, the MetS prevalence was found to be increased among schizophrenia patients over time, and the increase in the young age group was particularly striking. Among all of the factors investigated, nutritional status was found to play a major role in this increased prevalence.
Literature
1.
Osby U, Correia N, Brandt L et al (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–28CrossRef
2.
Laursen TM, Munk-Olsen T, Vestergaard M (2012) Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25:83–88CrossRef
3.
Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 10:425–448CrossRef
4.
Nielsen RE, Uggerby AS, Jensen SO, McGrath JJ et al (2013) Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades—a Danish nationwide study from 1980 to 2010. Schizophr Res 146:22–27CrossRef
5.
Walker ER, McGee RE, Druss BG (2015) Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72:334–341CrossRef
6.
von Hausswolff-Juhlin Y, Bjartveit M, Lindström E et al (2009) Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 438:15–21CrossRef
7.
IDF (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Brussels
8.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
9.
Grundy SM, Brewer B, Cleeman JL et al (2004) Definition of metabolic syndrome:report of the National Heart, Lung, And Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 109:433–438CrossRef
10.
Hanley AJ, Karter AJ, Williams K et al (2005) Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112:3713–3721CrossRef
11.
De Hert M, Schreurs V, Vancampfort D et al (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8:15–22CrossRef
12.
Mitchell AJ, Vancampfort D, Sweers K et al (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull 39:306–318CrossRef
13.
Srisurapanont M, Likhitsathian S, Boonyanaruthee V et al (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14CrossRef
14.
L’Italien GJ, Casey DE, Kan HJ et al (2007) Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 68:1510–1516CrossRef
15.
Meyer JM, Davis VG, Goff DC et al (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 10:273–286CrossRef
16.
Schorr SG, Slooff CJ, Bruggeman R et al (2009) The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43:1106–1111CrossRef
17.
Malhotra N, Grover S, Chakrabarti S et al (2013) Metabolic syndrome in schizophrenia. Indian J Psychol Med 35:227–240CrossRef
18.
Bioque M, García-Portilla MAP, García-Rizo C et al (2018) Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophr Res 193:188–196CrossRef
19.
20.
Yazici MK, Anil Yağcioğlu AE, Ertuğrul A et al (2011) The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 261:69–78CrossRef
21.
Kostakoğlu E, Batur S, Tiryaki A et al (1999) The validity and reliability of the Turkish adaptation of the positive and negative syndrome scale (PANSS). Türk Psikoloji Dergisi 14:23–32
22.
Lingjaerde O, Ahlfors UG, Bech P et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100CrossRef
23.
Saglam M, Arikan H, Savci S et al (2010) International physical activity questionnaire: reliability and validity of the Turkish version. Percept Mot Skills 111:278–284CrossRef
24.
Townsend P, Phillimore P, Beattie A (1988) Health and deprivation: inequality and the North. Routledge, London
25.
26.
Beslenme Bilgi Sistemi—BeBiS (2008) Versiyon 6.1; Ebispro for Windows, Entwickelt an der Universitat Hohenheim, Stuttgart; Turkish Version (BeBiS 6.1), Pasifik Dayanıklı Company (www.​bebis.​com.​tr); Istanbul
27.
Shi L, Ascher-Svanum H, Chiang YJ et al (2009) Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 9:80CrossRef
28.
Arango C, Bobes J, Aranda P et al (2008) CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 104:1–12CrossRef
29.
Grover S, Nebhinani N, Chakrabarti S et al (2014) Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India. Nord J Psychiatry 68:72–77CrossRef
30.
Caroff SN, Leong SH, Ng-Mak D et al (2018) Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness. Community Ment Health J 54:725–734CrossRef
31.
Bajaj S, Varma A, Srivastava A et al (2013) Association of metabolic syndrome with schizophrenia. Indian J Endocrinol Metab 17:890–895CrossRef
32.
Nasrallah HA (2007) The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 68(Suppl 1):5–11PubMed
33.
Sigman-Grant M, Morita J (2003) Defining and interpreting intakes of sugars. Am J Clin Nutr 78(4):815S–826SCrossRef
34.
O’Neil CE, Fulgoni VL 3rd, Nicklas TA (2011) Candy consumption was not associated with body weight measures, risk factors for cardiovascular disease, or metabolic syndrome in US adults: NHANES 1999–2004. Nutr Res 31:122–130CrossRef
35.
Yang Q, Zhang Z, Gregg EW et al (2014) Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 174:516–524CrossRef
36.
Basu S, Yoffe P, Hills N et al (2013) The relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data. PLoS One 8:e57873CrossRef
37.
Zhang Z, Gillespie C, Welsh JA et al (2015) Usual intake of added sugars and lipid profiles among the US adolescents: national health and nutrition examination survey, 2005–2010. J Adolesc Health 56:352–359CrossRef
Metadata
Title
A follow-up study of metabolic syndrome in schizophrenia
Authors
Gökhan Yoca
A. Elif Anıl Yağcıoğlu
Nurhayat Eni
Sevilay Karahan
İnci Türkoğlu
Emine Akal Yıldız
Seyit M. Mercanlıgil
M. Kâzım Yazıcı
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Keyword
Schizophrenia
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 5/2020
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-019-01016-x

Other articles of this Issue 5/2020

European Archives of Psychiatry and Clinical Neuroscience 5/2020 Go to the issue

Original Paper

Resilience and cortical thickness: a MRI study

Original Paper

Relationships between social stigma, stigma experience and self-stigma and impaired quality of life in schizophrenia across three Latin-American countries

Original Paper

The interaction between OXTR rs2268493 and perceived maternal care is associated with amygdala–dorsolateral prefrontal effective connectivity during explicit emotion processing

Original Paper

Maternal verbal aggression in early infancy and child’s internalizing symptoms: interaction by common oxytocin polymorphisms

Original Paper

Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study

Editorial

Impact of the metabolic syndrome on severe mental disorders